Milbexime human application — the ivermectin (avermectin derivative) and moxidectin (milbemycin derivative) for onchocerciasis (river blindness) and lymphatic filariasis mass drug administration representing the largest human anthelmintic program — creates the most commercially dynamic market segment, with the Milbexime Anthelmintic Market reflecting NTD elimination as the public-health-driven commercial driver.

Mectizan Donation Program — the Merck/MSD ivermectin donation of 4B+ tablets since 1987 for onchocerciasis elimination creating the pharmaceutical philanthropy model. 250M+ people treated annually in 30+ African countries, with 99% elimination of onchocerciasis in the Americas achieved, and the WHO 2021-2030 NTD roadmap targeting elimination in 12 African countries by 2030 demonstrates the public health commercial impact.

Moxidectin for onchocerciasis — the FDA-approved (2018) moxidectin tablet (8mg) as the first new treatment for river blindness in 20 years creating the next-generation option. Medicines Development for Global Health (MDGH) developing moxidectin with 4-6 month microfilaricidal suppression (vs 6-12 months for ivermectin), enabling less frequent MDA and potential for accelerated elimination, and the moxidectin + albendazole combination for lymphatic filariasis.

Lymphatic filariasis triple therapy — the ivermectin + albendazole + diethylcarbamazine (IDA) combination achieving >95% microfilarial clearance creating the accelerated elimination strategy. WHO recommending IDA for all LF-endemic countries except those with loiasis co-endemicity, with 600M+ people treated in 2022, and the potential for LF elimination by 2030.

Do you think moxidectin will replace ivermectin as the primary onchocerciasis treatment, or will the established ivermectin infrastructure, Merck donation program, and loiasis safety concerns maintain ivermectin dominance?

What are the specific human anthelmintic programs, their products, and elimination status? Onchocerciasis: Mectizan (ivermectin): Merck; donation; 1987; 4B+ tablets; 250M+ annually; 6-12 month; suppression; microfilariae; moxidectin: MDGH; FDA; 2018; 8mg; tablet; 4-6 month; suppression; longer; duration; less; frequent; MDA; potential; doxycycline: 4-6 week; course; Wolbachia; endosymbiont; elimination; macrofilaricidal; adult; worm; effect; not; mass; administration; feasible; Lymphatic filariasis: albendazole + ivermectin: annual; MDA; 5+ years; IDA: ivermectin + diethylcarbamazine + albendazole; triple; therapy; >95% clearance; 1-2 years; potential; moxidectin + albendazole: alternative; longer; suppression; research; Soil-transmitted helminths: albendazole: 400mg; annual; school-based; deworming; mebendazole: 500mg; alternative; ivermectin: co-administration; LF; onchocerciasis; programs; Schistosomiasis: praziquantel: 40mg/kg; annual; school-based; not; milbexime; but; major; NTD; program; Elimination status: onchocerciasis: Americas: 99% eliminated; 4 countries; remaining; Africa: 12 countries; targeted; 2030; elimination; 17 countries; ongoing; LF: 600M+ treated; 2022; 17 countries; eliminated; 2021; 33 countries; ongoing; target; 2030; STH: 800M+ children; at risk; school-based; deworming; 50%+ coverage; target; 75%+; Challenges: loiasis: Loa loa; co-endemicity; 10+ countries; ivermectin; severe; adverse; events; Loa; encephalopathy; death; risk; 1-2%; high; microfilarial; load; moxidectin: similar; risk; test-and-not-treat; required; LoaScope; mobile; phone; microscopy; RAPLOA; questionnaire; resistance: ivermectin; suboptimal; response; some; foci; 10-20 years; treatment; ongoing; research; needed; coverage: 65-75% MDA; coverage; target; 80%+; not; achieved; all; countries; conflict; insecurity; remote; access; challenges; Future: moxidectin: potential; primary; onchocerciasis; treatment; longer; duration; less; frequent; MDA; cost; effectiveness; analysis; ongoing; vaccine: onchocerciasis; vaccine; research; 20+ years; no; effective; vaccine; yet; early; stage; transmission: blocking; Wolbachia; target; novel; integrated: WASH; water; sanitation; hygiene; vector; control; tsetse; blackfly; integrated; NTD; program; not; drug; only; sustainability: country; ownership; domestic; financing; transition; from; donor; dependence; 2030+; target.